Depomed Acquires All Rights To Zipsor

DEPOMED Q1 13 Earnings Conference Call At 4:30 PM ET

Depomed To Present At ROTH Conference; Webcast At 2:30 PM ET

Depomed To Present At Cowen And Company Conference; Webcast At 10:00 AM ET

Trade DEPO now with

6/21/2012 4:33 PM ET

Depomed, Inc. (DEPO: Quote) Thursday said it acquired all rights to Zipsor liquid filled capsules from Xanodyne Pharmaceuticals, Inc., in return for $25.9 million of cash and potential milestone payments based on sales of Zipsor and assumption of certain liabilities.

Zipsor is a non-steroidal anti-inflammatory drug, known to relieve mild to moderate acute pain in adults.

Click here to receive FREE breaking news email alerts for DEPOMED INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 76 Articles

Editors Pick

Stocks May Move Lower As Upbeat Data Raises Fed Concerns - U.S. Commentary

After showing a substantial recovery over the course of the previous session, stocks are likely to come under pressure in early trading on Friday. The major index futures are currently pointing to a lower open for the markets, with the Dow futures down by 42 points.

Mailbox Now Comes To IPad

The popular e-mail management app Mailbox, developed by Orchestra Inc., has been updated to be compatible with Apple's iPad. Orchestra disclosed the news of the update through its official blog. "You asked, we listened. Mailbox is now available for iPad, so you can swipe your way to inbox zero on all your iOS devices," Orchestra's brief blog read.

German Business Morale Improves For First Time In 3 Months

Sentiment among German companies strengthened in May for the first time since February due to an improvement in current conditions, indicating that the economy remains on track despite a challenging environment. Moreover, the GfK survey forecast German optimism to reach its highest level in more than five years.